Clinical trial
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage…
NCT00393822 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00393822 |
|---|---|
| Title | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer |
| Official title | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Colon Cancer |
| Intervention type | Drug |
| Interventions | palifermin, placebo |
| Enrollment | 100 |
| Start date | Aug 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Mar 1, 2014 |
| First posted | Oct 30, 2006 |
| Last update posted | Jul 15, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: